西维斯健康公司宣布，其药房福利管理部门CVS Caremark将把Pyzchiva和Yesintek的生物类似药列为Stelara的优先替代药物。这一战略调整意味着，大多数医保计划参保成员在使用这些替代药物时无需支付任何费用。
该决策旨在通过推广成本效益更高的生物类似药，降低医疗支出压力。Pyzchiva与Yesintek的仿制药在临床效果上与原研药Stelara相当，但价格更具竞争力。此举预计将为医保计划和个人节省大量药品开支。
西维斯健康表示，此次调整将分阶段实施，确保患者用药的平稳过渡。参保人若坚持使用原研药Stelara，可能需承担更高的自付费用。公司强调将持续监测药物安全性和有效性，保障患者权益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.